semaglutide ban 2025 Novo Nordisk H1 2025: Unseats Keytruda from Top with USD 16.7b in Sales FDA Approves Wegovy Weight-Loss Pill

In addition to the abdomen, this procedure treats the lower back, waist, hips, and buttocks all in one procedure

Another 37% showed measurable improvement in liver fibrosis

Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535

Many candidates also experience persistent cravings, insulin resistance, or metabolic slowing that GLP-1 therapy may help address

No, Medicare generally does not cover GLP-1 medications for weight loss

Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus Inform patients with diabetes insipidus and their caregivers to contact their healthcare provider if changes in fluid intake or urine output or other signs of dehydration, mental status changes (e.g., confusion, lethargy), or significant nausea and vomiting occur which may require adjustments in concomitant therapies during treatment with IMCIVREE [see Warnings and Precautions (5.6)]